Bigmar, Inc. Signs Letter of Intent to Form Strategic Alliance With Graminex, a Phytopharmaceutical Company.JOHNSTOWN, Ohio--(BW HealthWire)--August 20, 1998--Bigmar, Inc. (Nasdaq SmallCap Market:BGMR/Boston Stock Exchange:BGM) today announced it signed a letter of intent on August 17, 1998, to form a strategic alliance with Graminex, a manufacturer and supplier of botanical raw materials containing proprietary active pharmaceutical substances, based in Deshler, Ohio Deshler is a village in Henry County, Ohio, United States. The population was 1,831 at the 2000 census. Geography Deshler is located at (41.207011, -83.902445)GR1. . The proposed alliance between Bigmar and Graminex is contemplated for the commercialization of proprietary products of common interests. Terms of the proposed relationship were not disclosed and are subject to due diligence Research; analysis; your homework. This term has caught on in all industries, because it sounds so "wired." Who would want to do analysis or research when they can do due diligence. See wired. review, negotiations and approval by Bigmar's Board of Directors. John G. Tramontana, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of the Company, commented, "This collaboration with a company that has one of the most advanced botanical raw material processing plants in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. will help Bigmar achieve its long-term development goals. A number of marketed oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. products are the result of research in the area of phytopharmaceuticals, therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. based on plant material. We are delighted that Graminex has chosen our Company for this partnership, and we are confident that due diligence activities will lead to a signed collaboration agreement." BIGMAR, Inc.'s strategy is to supply world markets with a full line of high quality, affordably priced pharmaceutical products focusing on oncology. With distribution rights to more than 20 generic oncological products, the Company intends to manufacture, in its state- of-the-art facilities in Switzerland, and market through pharmaceutical company partners in Europe and the United States, off- patent generic oncological drugs and additional oncological drugs as their patents expire. Forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. involve known and unknown risks, uncertainties and other factors as detailed in the Company's SEC reports and filings, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied in such forward-looking statements.
CONTACT: Bigmar, Inc., Johnstown
William R. Ash, III
(740) 966-5800
or
Investor Relations Contact:
The Equity Group Inc., New York
Ethan Denkensohn
(212) 836-9611
edenkensohn@equityny.com
|
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion